Anti-IL-5 Open-Label Study for Hypereosinophilic Syndrome
What is the purpose of this study?
GSK will sponsor this compassionate use trial of mepolizumab to treat subjects with HES who have significant clinical disease due to HES, are unresponsive to medication used to treat HES and those who have demonstrated clinical benefit with previous anti IL-5 treatment. The overall objective of this compassionate use supply program is to assess the safety and effectiveness of treatment with Mepolizumab in subjects with severe HES and subjects who previously benefited from anti-IL5 therapy.
Who can participate?
- > 12 years of age
- Meets the diagnostic criteria for Hypereosinophilic Syndrome (HES)
- Has ongoing HES, as judged by documented treatment failure defined as life-threatening or severely disabling signs of HES
OR
- Has previously received mepolizumab through compassionate access or who previously received the Schering-Plough anti IL-5 (SCH55700) compound and who has shown evidence of clinical.
Conditions
- Eosinophilic Disorders
- Medications
Who should I contact for more information?
If you are a patient who may be interested in enrolling in this research study or you have further questions, please contact us:
Marc E. Rothenberg, MD, PhD
Date
Ongoing
